Loading the map…
Residential care activities for learning difficulties, mental health and substance abuse · Glasgow
Osarugue
Osarugue Limited
Private limited company registered in Glasgow, classed under “Residential care activities for learning difficulties, mental health and substance abuse”.
Headline figures
FY to Jan 2026 · Company only
Turnover
For subscribers
Profit after tax
£18.7k
Net assets
For subscribers
Cash
For subscribers
Employees
For subscribers
What the numbers say
1 finding from the figures, in plain English
Written by rules from the figures on this page. Not a forecast or a credit opinion.
History
| £ | 2026 |
|---|---|
| Profit after tax | £18.7k |
| Turnover | |
| Net assets | |
| Cash | |
| Employees |
Every figure for the year
“—” means we did not find the figure in a source; it is never filled with an estimate.
Balance sheet and ratios
From the filed balance sheets · £
| Balance sheet | 2026 |
|---|---|
| Fixed assets | |
| Ratios | |
| Profit marginProfit after tax as a share of turnover | |
| Return on equityProfit after tax as a share of net assets | |
| Turnover per employeeTurnover divided by average staff | |
1 balance-sheet lines and 3 ratios, every year
A ratio appears only for years where every line it needs was filed. Lines are as tagged in the accounts; nothing is added up or estimated.
Questions people ask
›What does Osarugue do?
Private limited company registered in Glasgow, classed under “Residential care activities for learning difficulties, mental health and substance abuse”.
›How much turnover does Osarugue make?
Answered in the full report
›Is Osarugue profitable?
Yes: it made a profit after tax of £18.7k in the year to 31 January 2026, its latest filed accounts.
›How many people work at Osarugue?
Answered in the full report
›Where is Osarugue based?
Its registered office is 29 Bilsland Close, Glasgow, G20 9AF, in Glasgow.
›When was Osarugue founded?
Osarugue Limited was incorporated on 20 January 2025.
›Is Osarugue still trading?
The register lists Osarugue Limited as active.